1. Academic Validation
  2. Impurity profile tracking for active pharmaceutical ingredients: case reports

Impurity profile tracking for active pharmaceutical ingredients: case reports

  • J Pharm Biomed Anal. 2007 Jun 28;44(2):421-9. doi: 10.1016/j.jpba.2006.11.004.
Lili Zhou 1 Bing Mao Robert Reamer Tom Novak Zhihong Ge
Affiliations

Affiliation

  • 1 Merck Research Laboratories, Early Development Analytical Research, P.O. Box 2000, RY818-B225, Rahway, NJ 07065, USA. lili_zhou@merck.com
Abstract

Tracking the impurity profile of an active pharmaceutical ingredient (API) is a very important task for all stages of drug development. A systematic approach for tracking impurity profile of API is described. Various real pharmaceutical applications are presented through successful examples of impurity profile tracking for three different novel APIs. These include MK-0969, an M3 antagonist; MK-0677, an oral-active growth hormone secretagogue and API-A, a Cathepsin K Inhibitor. A general strategy including selection of a reversed phase high performance liquid chromatographic (RP-HPLC) impurity profile method based on screening various stationary phases and changing the pH of the mobile phase and elucidation of impurity structures through the utilization of LC-MS, preparative-LC and NMR is demonstrated. A series of studies were conducted on the peak purity check by using the LC-UV diode-array and LC-MS detections. The advantages and disadvantages of each technique in the evaluation of peak purity are discussed.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-120322
    M3 Antagonist